Histological Outcome of Fuzheng Huayu plus Entecavir Combination Therapy in Chronic Hepatitis B Patients with Significant Liver Fibrosis

作者：Honglian Gui, Changqing Zhao, Yan Wang, Hong-Tu Gu, Weijing Wang, Wei Cai, Qing Guo, Shisan Bao, Lieming Xu, Qing Xie · 发表于：Journal of Clinical and Translational Hepatology · 年份：2020 · DOI：10.14218/jcth.2020.00004 · 被引用次数：27 · 研究领域：Hepatitis B Virus Studies、Liver Disease Diagnosis and Treatment、Drug-Induced Hepatotoxicity and Protection

The combination therapy of FZHY plus ETV for 48 weeks resulted in a higher rate of necroinflammatory improvement and fibrosis regression than ETV alone in chronic hepatitis B patients with significant fibrosis/cirrhosis. The clinical trial number is ChiCTR-TRC-11001377.